Chronic pancreatitis and cystic fibrosis

Gut

Volumn 52, Issue SUPPL. 2, 2003, Pages

  Witt, H ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ALPHA 1 ANTITRYPSIN; APROTININ; ENZYME PRECURSOR; SERINE PROTEINASE INHIBITOR; TRANSMEMBRANE CONDUCTANCE REGULATOR; TRYPSIN INHIBITOR; TRYPSINOGEN;

AGENESIS; ASTHMA; AUTOSOMAL RECESSIVE DISORDER; BRONCHIECTASIS; BRONCHOPULMONARY ASPERGILLOMA; CHRONIC LIVER DISEASE; CHRONIC PANCREATITIS; CONFERENCE PAPER; CYSTIC FIBROSIS; DISEASE COURSE; DISEASE SEVERITY; FAMILY HISTORY; GENE EXPRESSION; GENE MUTATION; GENOTYPE; HUMAN; MECONIUM ILEUS; MORTALITY; PANCREAS INSUFFICIENCY; PARENCHYMA; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; SARCOIDOSIS; VAS DEFERENS;

EID: 18144434576     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.52.suppl_2.ii31     Document Type: Conference Paper

References (166)

1. Ammann RW, Bühler H, Münch R, et al. Differences of the natural history of idiopathic (nonalcoholic) and alcoholic chronic pancreatitis. A comparative long-term study of 287 patients. Pancreas 1987;2:368-77.
2. Durbec JP, Sarles H. Multicenter survey on the etiology of pancreatic diseases. Relationship between the relative risk of developing chronic pancreatitis and alcohol, protein, and lipid consumption. Digestion 1978;18:337-50.
3. Singer MV, Gyr K, Sarles H. Revised classification of pancreatitis. Report of the Second International Symposium on the Classification of Pancreatitis in Marseille, France, March 28-30, 1984. Gastroenterology 1985;89:683-5.
4. Comfort MW, Steinberg AG. Pedigree of a family with hereditary chronic relapsing pancreatitis. Gastroenterology 1952;21:54-63.
5. Chiari H. Über Selbstverdauung des menschlichen Pankreas. Zeitschrift für Heilkunde 1896;17:69-96.
6. Steer ML, Meldolesi J. The cell biology of experimental pancreatitis. N Engl J Med 1987;316:144-50.
7. Scheele GA, Bartelt D, Bieger W. Characterization of human exocrine pancreatic proteins by two-dimensional isoelectric focusing/SDS gel elctrophoresis. Gastroenterology 1981;80:461-73.
8. Colomb E, Guy O, Deprez P, et al. The two human trypsinogens: catalytic properties of the corresponding trypsins. Biochim Biophys Acta 1978;525:186-93.
9. Colomb E, Figarella C. Comparative studies on the mechanism of activation of the two human trypsinogens. Biochim Biophys Acta 1979;571:343-51.
10. Whitcomb DC, Preston RA, Aston CE, et al. A gene for hereditary pancreatitis maps to chromosome 7q35. Gastroenterology 1996;110:1975-80.
11. Le Bodic L, Bignon JD, Raguénès O, et al. The hereditary pancreatitis gene maps to long arm of chromosome 7. Hum Mol Genet 1996;5:549-54.
12. Pandya A, Blanton SH, Landa B, et al. Linkage studies in a large kindred with hereditary pancreatitis confirms mapping of the gene to a 16-cM region on 7q. Genomics 1996;38:227-30.
13. Whitcomb DC, Gorry MC, Preston RA, et al. Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. Nat Genet 1996;14:141-5.
14. Gorry MC, Gabbaizedeh D, Furey W, et al. Mutations in the cationic trypsinogen gene are associated with recurrent acute and chronic pancreatitis. Gastroenterology 1997;113:1063-8.
15. Teich N, Mössner J, Keim V. Mutations of the cationic trypsinogen in hereditary pancreatitis. Hum Mut 1998;12:39-43.
16. Witt H, Luck W, Becker M. A signal peptide cleavage site mutation in the cationic trypsinogen gene is strongly associated with chronic pancreatitis. Gastroenterology 1999;117:7-10.
17. Férec C, Raguénès O, Salomon R, et al. Mutations in the cationic trypsinogen gene and evidence for genetic heterogeneity in hereditary pancreatitis. J Med Genet 1999;36:228-32.
18. Teich N, Ockenga J, Hoffmeister A, et al. Chronic pancreatitis associated with an activation peptide mutation that facilitates trypsin activation. Gastroenterology 2000;119:461-5.
19. Chen JM, Piepoli Bis A, Le Bodic L, et al. Mutational screening of the cationic trypsinogen gene in a large cohort of subjects with idiopathic chronic pancreatitis. Clin Genet 2001;59:189-93.
20. Le Maréchal C, Bretagne JF, Raguénès O, et al. Identification of a novel pancreatitis-associated missense mutation, R116C, in the human cationic trypsinogen gene (PRSS1). Mol Genet Metab 2001;74:342-4.
21. Le Maréchal C, Chen JM, Quéré I, et al. Discrimination of three mutational events that result in a disruption of the R122 primary autolysis site of the human cationic trypsinogen (PRSS1) by denaturing high performance liquid chromatography. BMC Genet 2001;2:19.
22. Tautermann G, Ruebsamen H, Beck M, et al. R116C mutation of cationic trypsinogen in a Turkish family with recurrent pancreatitis illustrates genetic microheterogeneity of hereditary pancreatitis. Digestion 2001;64:226-32.
23. Simon P, Weiss FU, Sahin-Tóth M, et al. Hereditary pancreatitis caused by a novel PRSS1 mutation (Arg-122 → Cys) that alters autoactivation and autodegradation of cationic trypsinogen. J Biol Chem 2002;277:5404-10.
24. Pfützer R, Myers E, Applebaum-Shapiro S, et al. Novel cationic trypsinogen (PRSS1) N29T and R122C mutations cause autosomal dominant hereditary pancreatitis. Gut 2002;50:271-2.
25. Teich N, Bauer N, Mössner J, et al. Mutational screening of patients with nonalcoholic chronic pancreatitis: identification of further trypsinogen variants. Am J Gastroenterol 2002;97:341-6.
26. Sahin-Tóth M. Human cationic trypsinogen. Role of Asn-21 in zymogen activation and implications in hereditary pancreatitis. J Biol Chem 2000;275:22750-5.
27. Sahin-Tóth M, Tóth M. Gain-of-function mutations associated with hereditary pancreatitis enhance autoactivation of human cationic trypsinogen. Biochem Biophys Res Commun 2000;278:286-9.
28. Szilágyi L, Kénesi E, Katona G, et al. Comparative in vitro studies on native and recombinant human cationic trypsins. Cathepsin B is a possible pathological activator of trypsinogen in pancreatitis. J Biol Chem 2001;276:24574-80.
29. Simon P, Weiss FU, Sahin-Tóth M, et al. Hereditary pancreatitis caused by a novel PRSS1 mutation (Arg-122 → Cys) that alters autoactivation and autodegradation of cationic trypsinogen. J Biol Chem 2002;277:5404-10.
30. Kukor Z, Tóth M, Pál G, et al. Human cationic trypsinogen. Arg(117) is the reactive site of an inhibitory surface loop that controls spontaneous zymogen activation. J Biol Chem 2002;277:6111-17.
31. Kazal LA, Spicer DS, Brahinsky RA. Isolation of a crystalline trypsin inhibitor-anticoagulant protein from the pancreas. J Am Chem Soc 1948;70:304-40.
32. Bartelt DC, Shapanka R, Greene LJ. The primary structure of the human pancreatic secretory trypsin inhibitor. Amino acid sequence of the reduced S-aminoethylated protein. Arch Biochem Biophys 1977;179:189-99.
33. Laskowski M, Wu FC. Temporary inhibition of trypsin. J Biol Chem 1953;204:797-805.
34. Witt H, Luck W, Hennies HC, et al. Mutations in the gene encoding the serine protease inhibitor, Kazal type 1 are associated with chronic pancreatitis. Nat Genet 2000;25:213-16.
35. Pfützer RH, Barmada NM, Brunskill APJ, et al. SPINK1/PSTI polymorphisms act as disease modifiers in familial and idiopathic chronic pancreatitis. Gastroenterology 2000;119:615-23.
36. Chen JM, Mercier B, Audrézet MP, et al. Mutations of the pancreatic secretory trypsin inhibitor (PSTI) gene in idiopathic chronic pancreatitis. Gastroenterology 2001;120:1061-4.
37. Drenth JPH, te Morsche R, Jansen JBMJ. Mutations in serine protease inhibitor Kazal type 1 are strongly associated with chronic pancreatitis. Gut 2002;50:687-92.
38. Threadgold J, Greenhalf W, Ellis I, et al. The N34S mutation of SPINK1 (PSTI) is associated with a familial pattern of idiopathic chronic pancreatitis but does not cause the disease. Gut 2002;50:675-81.
39. Chen JM, Mercier B, Audrézet MP, et al. Mutational analysis of the human pancreatic secretory trypsin inhibitor (PSTI) gene in hereditary and sporadic chronic pancreatitis. J Med Genet 2000;37:67-9.
40. Kuwata K, Hirota M, Sugita H, et al. Genetic mutations in exons 3 and 4 of the pancreatic secretory trypsin inhibitor in patients with pancreatitis. J Gastroenterol 2001;36:612-18.
41. Ockenga J, Dörk T, Stuhrmann M. Low prevalence of SPINK1 gene mutations in adult patients with chronic idiopathic pancreatitis. J Med Genet 2001;38:243-4.
42. Kaneko K, Nagasaki Y, Furukawa T, et al. Analysis of the human pancreatic secretory trypsin inhibitor (PSTI) gene mutations in Japanese patients with chronic pancreatitis. J Hum Genet 2001;46:293-7.
43. Audrézet MP, Chen JM, Le Maréchal C, et al. Determination of the relative contribution of three genes-the cystic fibrosis transmembrane conductance regulator gene, the cationic trypsinogen gene, and the pancreatic secretory trypsin inhibitor gene-to the etiology of idiopathic chronic pancreatitis. Eur J Hum Genet 2002;10:100-6.
44. Sharer N, Schwarz M, Malone G, et al. Mutations of the cystic fibrosis gene in patients with chronic pancreatitis. N Engl J Med 1998;339:645-52.
45. Cohn JA, Friedman K, Noone P, et al. Relation between mutations of the cystic fibrosis gene and idiopathic pancreatitis. N Engl J Med 1998;339:653-8.
46. Bank S, Marks IN, Novis B. Sweat electrolytes in chronic pancreatitis. Am J Dig Dis 1978;23:178-81.
47. Nakamura K, Sarles H, Payan H. Three-dimensional reconstruction of the pancreatic ducts in chronic pancreatitis. Gastroenterology 1972;62:942-9.
48. de Angelis C, Valente G, Spaccapietra M, et al. Histological study of alcoholic, nonalcoholic, and obstructive chronic pancreatitis. Pancreas 1992;7:193-6.
49. Shwachman H, Lebenthal E, Khaw W. Recurrent acute pancreatitis in patients with cystic fibrosis with normal pancreatic enzymes. Pediatrics 1975;55:86-94.
50. Atlas AB, Orenstein SR, Orenstein DM. Pancreatitis in young children with cystic fibrosis. J Pediatr 1992;120:756-9.
51. Kiesewetter S, Macek M Jr, Davis C, et al. A mutation in CFTR produces different phenotypes depending on chromosomal background Nat Genet 1993;5:274-8.
52. Noone PG, Zhou Z, Silverman LM, et al. Cystic fibrosis gene mutations and pancreatitis risk: relation to epithelial ion transport and trypsin inhibitor gene mutations. Gastroenterology 2001;121:1310-19.
53. 1-antitrypsin deficiency in Europe: geographical distribution of Pi types S and Z. Respir Med 1998;92:367-77.
54. Novis BH, Young GO, Bank S, et al. Chronic pancreatitis and alpha-1-antitrypsin. Lancet 1975;ii:748-9.
55. 1-antitrypsin and chronic pancreatitis. Lancet 1976;ii:1032-3.
56. 1-antitrypsin in pancreatitis. Digestion 1982;23:93-6.
57. 1-antitrypsin in pancreatic diseases. Digestion 1978;18:138-40.
58. 1 antitrypsin phenotypes and alcoholic pancreatitis. Gut 1991;32:945-8.
59. 1-antitrypsin genotypes in patients with chronic pancreatitis. Scand J Gastroenterol 2002;37:356-9.
60. Teich N, Walther K, Bödeker H, et al. Relevance of variants in serum antiproteinases for the course of chronic pancreatitis. Scand J Gastroenterol 2002;37:360-5.
61. Larsson C. Natural history and life expectancy in severe alpha-1-antitrypsin deficiency, Pi Z. Acta Med Scand 1978;204:345-51.
62. Matthew P, Wyllie R, Caulfield M, et al. Chronic pancreatitis in late childhood and adolescence. Clin Pediatr 1994;33:88-94.
63. Witt H, Hennies HC, Becker M. SPINK1 mutations in chronic pancreatitis (letter). Gastroenterology 2001;120:1060-1.
64. Rinderknecht H. Pancreatic secretory enzymes. In: Go VLW, et al, eds). The pancreas: biology, pathobiology, and disease. New York: Raven, 1993:219-51.
65. Laskowski M Jr, Kato I. Protein inhibitors of proteinases. Annu Rev Biochem 1980;49:593-626.
66. Rinderknecht H. Activation of pancreatic zymogens. Normal activation, premature intrapancreatic activation, protective mechanisms against inappropriate activation. Dig Dis Sci 1986;31:314-21.
67. Freedman SD, Blanco P, Shea JC, et al. Mechanisms to explain pancreatic dysfunction in cystic fibrosis. Gastroenterol Clin North Am 2000;84:657-64
68. Ammann RW. A clinically based classification system for alcoholic chronic pancreatitis: summary of an international workshop on chronic pancreatitis. Pancreas 1997;14:215-21.
69. Teich N, Mössner J, Keim V. Screening for mutations of the cationic trypsinogen gene: are they of relevance in chronic alcoholic pancreatitis? Gut 1999;44:413-16.
70. Keim V, Hoffmeister A, Teich N, et al. The pancreatitis-associated protein in hereditary and chronic alcoholic pancreatitis. Pancreas 1999;19:248-54.
71. Norton ID, Apte MV, Dixson H, et al. Cystic fibrosis genotypes and alcoholic pancreatitis. J Gastroenterol Hepatol 1998;13:496-9.
72. Haber P, Wilson J, Apte M, et al. Individual susceptibility to alcoholic pancreatitis: still an enigma. J Lab Clin Med 1995;125:305-12.
73. Witt H, Luck W, Becker M, et al. Mutation in the SPINK1 trypsin inhibitor gene, alcohol use, and chronic pancreatitis. JAMA 2001;285:2716-17.
74. Rinderknecht H, Stace NH, Renner IG. Effects of alcohol abuse on exocrine pancreatic secretion in man. Dig Dis Sci 1985;50:65-71.
75. Sarner M, Cotton PB. Classification of pancreatitis. Gut 1984;25:756-9.
76. Sarles H, Adler G, Dani R, et al. The pancreatitis classification of Marseilles-Rome 1988. Scand J Gastroenterol 1989;24:641-2.
77. Sarles H, Adler G, Dani R, et al. Classifications of pancreatitis and definition of pancreatic diseases. Digestion 1989;43:234-6.
78. Comfort MW, Gambill EE, Baggenstoss AH. Chronic relapsing pancreatitis: a study of 29 cases without associated disease of the biliary or gastrointestinal tract. Gastroenterology 1946;6:239-85.
79. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989;245:1066-73.
80. Kerem BS, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: genetic analysis. Science 1989;245:1073-80.
81. Zielenski J, Rozmahel R, Bozon D, et al. Genomic DNA sequence of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Genomics 1991;10:214-28.
82. Riordan JR. The cystic fibrosis transmembrane conductance regulator. Annu Rev Physiol 1993;55:609-30.
83. Sheppard DN, Welsh MJ. Structure and function of the CFTR chloride channel. Physiol Rev 1999;79:S23-45.
84. The Cystic Fibrosis Genetic Analysis Consortium. Population variation of common cystic fibrosis mutations. Hum Mutat 1994;4:167-77.
85. Welsh M, Smith A. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 1993;73:1251-4.
86. Wilschanski M, Zielenski J, Markiewicz D, et al. Correlation of sweat chloride concentration with classes of the cystic fibrosis transmembrane conductance regulator gene mutations. J Pediatr 1995;127:705-10.
87. Mickle JE, Cutting GR. Genotype-phenotype relationships in cystic fibrosis. Med Clin North Am 2000;84:597-607.
88. Cheng SH, Gregory RJ, Marshall J, et al. Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell 1990;63:827-34.
89. Fulmer SB, Schwiebert EM, Morales MM, et al. Two cystic fibrosis transmembrane conductance regulator mutations have different effects on both pulmonary phenotype and regulation of outwardly rectified chloride currents. Proc Natl Acad Sci USA 1995;92:6832-6.
90. The Cystic Fibrosis Genotype-Phenotype Consortium. Correlation between genotype and phenotype in patients with cystic fibrosis. N Engl J Med 1993;329:1308-13.
91. Ferrari M, Colombo C, Sebastio G, et al. Cystic fibrosis patients with liver disease are not genetically distinct. Am J Hum Genet 1991;48:815-16.
92. Duthie A, Doherty DG, williams C, et al. Genotype analysis for delta F508, G551D and R553X mutations in children and young adults with cystic fibrosis with and without chronic liver disease. Hepatology 1992;15:660-4.
93. Colombo C, Apostolo MG, Ferrari M, et al. Analysis of risk factors for the development of liver disease associated with cystic fibrosis. J Pediatr 1994;124:393-9.
94. Wilschanski M, Rivlin J, Cohen S, et al. Clinical and genetic risk factors for cystic fibrosis-related liver disease. Pediatrics 1999;103:52-7.
95. Waters DL, Dorney SF, Gruca MA, et al. Hepatobiliary disease in cystic fibrosis patients with pancreatic sufficiency. Hepatology 1995;21:963-9.
96. Duthie A, Doherty DG, Donaldson PT, et al. The major histocompatibility complex influences the development of chronic liver disease in male children and young adults with cystic fibrosis. J Hepatol 1995;23:532-7.
97. Gabolde M, Hubert D, Guilloud-Bataille M, et al. The mannose binding lectin gene influences the severity of chronic liver disease in cystic fibrosis. J Med Genet 2001;38:310-11.
98. Holslcaw D, Eckstein H, Nixon HH. Meconium ileus: a 20 year review of 109 cases. Am J Dis Child 1965;109:101-13.
99. Kerem E, Corey M, Kerem B, et al. Clinical and genetic comparisons of patients with cystic fibrosis, with or without meconium ileus. J Pediatr 1989;114:767-73.
100. Kristidis P, Bozon D, Corey M, et al. Genetic determination of exocrine pancreatic function in cystic fibrosis. Am J Hum Genet 1992;50:1178-84.
101. Zielenski J, Corey M, Rozmahel R, et al. Detection of a cystic fibrosis modifier locus for meconium ileus on human chromosome 19q13. Nat Genet 1999;22:128-9.
102. Rohlfs EM, Shaheen NJ, Silverman LM. Is the hemochromatosis gene a modifier locus for cystic fibrosis? Genet Test 1998;2:85-8.
103. Lester LA, Kraut J, Lloyd-Still J, et al. Delta F508 genotype does not predict disease severity in an ethnically diverse cystic fibrosis population. Pediatrics 1994;93:114-18.
104. Koch C, Cuppens H, Rainisio M, et al. European Epidemiologic Registry of Cystic Fibrosis (ERCF): comparison of major disease manifestations between patients with different classes of mutations. Pediatr Pulmonol 2001;31:1-12.
105. Aron Y, Polla BS, Bienvenu T, et al. HLA class II polymorphism in cystic fibrosis: a possible modifier of pulmonary phenotype. Am J Respir Crit Care Med 1999;159:1464-8.
106. Döring G, Krogh-Johansen H, Weidinger S, et al. Allotypes of alpha 1-antitrypsin in patients with cystic fibrosis, homozygous and heterozygous for deltaF508. Pediatr Pulmonol 1994;18:3-7.
107. Mahadeva R, Westerbeek RC, Perry DJ, et al. Alpha1-antitrypsin deficiency alleles and the Taq-I G→A allele in cystic fibrosis lung disease. Eur Respir J 1998;11:873-9.
108. Mahadeva R, Stewart S, Bilton D, et al. Alpha-1 antitrypsin deficiency alleles and severe cystic fibrosis lung disease. Thorax 1998;53:1022-4.
109. Mahadeva R, Sharples L, Ross-Russell RI, et al. Association of alpha(1)-antichymotrypsin deficiency with milder lung disease in patients with cystic fibrosis. Thorax 2001;56:53-8.
110. Wilson AG, Symons JA, McDowell T, et al. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA 1997;94:3195-9.
111. Hull J, Thomson AH. Contribution of genetic factors other than CFTR to disease severity in cystic fibrosis. Thorax 1998;53:1018-21.
112. Ignotz RA, Massague J. Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem 1986;261:4337-45.
113. Arkwright PD, Laurie S, Super M, et al. TGF-beta(1) genotype and accelerated decline in lung function of patients with cystic fibrosis. Thorax 2000;55:459-62.
114. Awad MR, El-Gamel A, Hasleton P, et al. Genotypic variation in the transforming growth factor-beta1 gene: association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation 1998;66:1014-20.
115. Seidegard J, Vorachek WR, Pero RW, et al. Hereditary differences in the expression of the human glutathione transferase active on trans-stilbene oxide are due to a gene deletion. Proc Nat Acad Sci USA 1988;85:7293-7.
116. Strange RC, Matharoo B, Faulder GC, et al. The human glutathione S-transferases: a case-control study of the incidence of the GST1 0 phenotype in patients with adenocarcinoma. Carcinogenesis 1991;12:25-8.
117. Heagerty AH, Fitzgerald D, Smith A, et al. Glutathione S-transferase GSTM1 phenotypes and protection against cutaneous tumours. Lancet 1994;343:266-8.
118. Baranov VS, Ivaschenko T, Bakay B, et al. Proportion of the GSTM1 0/0 genotype in some Slavic populations and its correlation with cystic fibrosis and some multifactorial diseases. Hum Genet 1996;97:516-20.
119. Strange RC, Faulder CG, Davis BA, et al. The human glutathione S-transferases: studies on the tissue distribution and genetic variation of the GST1, GST2 and GST3 isozymes. Ann Hum Genet 1984;48:11-20.
120. Balfour-Lynn IM, Laverty A, Dinwiddie R. Reduced upper airway nitric oxide in cystic fibrosis. Arch Dis Child 1996;75:319-22.
121. Grasemann H, Knauer N, Büscher R, et al. Airway nitric oxide levels in cystic fibrosis patients are related to a polymorphism in the neuronal nitric oxide synthase gene. Am J Respir Crit Care Med 2000;162:2172-6.
122. Garred P, Pressler T, Madsen HO, et al. Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis. J Clin Invest 1999;104:431-7.
123. Gabolde M, Guilloud-Bataille M, Feingold J, et al. Association of variant alleles of mannose binding lectin with severity of pulmonary disease in cystic fibrosis: cohort study. BMJ 1999;319:1166-7.
124. Hawgood S, Poulain FR. The pulmonary collectins and surfactant metabolism. Annu Rev Physiol 2001;63:495-519.
125. Sumiya M, Super M, Tabona P, et al. Molecular basis of opsonic defect in immunodeficient children. Lancet 1991;337:1569-70.
126. Garred P, Madsen HO, Hofmann B, et al. Increased frequency of homozygosity of abnormal mannan-binding protein alleles in patients with suspected immunodeficiency. Lancet 1995;346:941-3.
127. Summerfield JA, Ryder S, Sumiya M, et al. Mannose binding protein gene mutations associoted with unusual and severe infections in adults. Lancet 1995;345:886-9.
128. Garred P, Madsen HO, Balslev U, et al. Susceptibility to HIV infection and progression of AIDS in relation to variant alleles of mannose-binding lectin. Lancet 1997;349:236-40.
129. Lipscombe RJ, Sumiya M, Hill AV, et al. High frequencies in African and non-African populations of independent mutations in the mannose binding protein gene. Hum Mol Genet 1992;1:709-15.
130. Madsen HO, Garred P, Kurtzhals JA, et al. A new frequent allele is the missing link in the structural polymorphism of the human mannan-binding protein. Immunogenetics 1994;40:37-44.
131. Madsen HO, Garred P, Thiel S, et al. Interplay between promoter and structural gene variants control basal serum level of mannan-binding protein. J Immunol 1995;155:3013-20.
132. Madsen HO, Satz ML, Hogh B, et al. Different molecular events result in low protein levels of mannan-binding lectin in populations from Southeast Africa and South America. J Immunol 1998;161:3169-75.
133. Kaplan E, Shwachman H, Perlmutter AD, et al. Reproductive failure in males with cystic fibrosis. N Engl J Med 1968;279:65-9.
134. Dumur V, Gervais R, Rigor JM, et al. Abnormal distribution of CF delta F508 allele in azoospermic men with congenital aplasia of epididymis and vas deferens. Lancet 1990;336:512.
135. Culard JF, Desgeorges M, Costa P, et al. Analysis of the whole CFTR coding regions and splice junctions in azoospermic men with congenital bilateral aplasia of epididymis or vas deferens. Hum Genet 1994;93:467-70.
136. Mercier B, Verlingue C, Lissens W, et al. Is congenital bilateral absence of vas deferens a primary form of cystic fibrosis? Analyses of the CFTR gene in 67 patients. Am J Hum Genet 1995;56:272-7.
137. Costes B, Girodon E, Ghanem N, et al. Frequent occurrence of the CFTR intron 8 (TG)n 5T allele in men with congenital bilateral absence of the vas deferens. Eur J Hum Genet 1995;3:285-93.
138. Casals T, Bassas L, Ruiz-Romero J, et al. Extensive analysis of 40 infertile patients with congenital absence of the vas deferens: in 50% of cases only one CFTR allele could be detected. Hum Genet 1995;95:205-11.
139. Chillon M, Casals T, Mercier B, et al. Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens. N Engl J Med 1995;332:1475-80.
140. Zielenski J, Patrizio P, Corey M, et al. CFTR gene variant for patients with congenital absence of vas deferens. Am J Hum Genet 1995;57:958-60.
141. Chu CS, Trapnell BC, Murtagh JJ Jr, et al. Variable deletion of exon 9 coding sequences in cystic fibrosis transmembrane conductance regulator gene mRNA transcripts in normal bronchial epithelium. EMBO J 1991;10:1355-63.
142. Chu CS, Trapnell BC, Curristin S, et al. Genetic basis of variable exon 9 skipping in cystic fibrosis transmembrane conductance regulator mRNA. Nat Genet 1993;3:151-6.
143. Strong TV, Wilkinson DJ, Mansoura MK, et al. Expression of an abundant alternatively spliced form of the cystic fibrosis transmembrane conductance regulator (CFTR) gene is not associated with a cAMP-activated chloride conductance. Hum Mol Genet 1993;2:225-30.
144. Poller W, Faber JP, Scholz S, et al. Sequence analysis of the cystic fibrosis gene in patients with disseminated bronchiectatic lung disease. Application in the identification of a cystic fibrosis patient with atypical clinical course. Klin Wochenschr 1991,69:657-63.
145. Pignatti PF, Bombieri C, Marigo C, et al. Increased incidence of cystic fibrosis gene mutations in adults with disseminated bronchiectasis. Hum Mol Genet 1995;4:635-9.
146. Pignatti PF, Bombieri C, Benetazzo M, et al. CFTR gene variant IVS8-5T in disseminated bronchiectasis. Am J Hum Genet 1996;58:889-92.
147. Girodon E, Cazeneuve C, Lebargy F, et al. CFTR gene mutations in adults with disseminated bronchiectasis. Eur J Hum Genet 1997;5:149-55.
148. Bombieri C, Benetazzo M, Saccomani A, et al. Complete mutational screening of the CFTR gene in 120 patients with pulmonary disease. Hum Genet 1998;103:718-22.
149. Tzetis M, Efthymiadou A, Strofalis S, et al. CFTR gene mutations - including three novel nucleotide substitutions - and haplotype background in patients with asthma, disseminated bronchiectasis and chronic obstructive pulmonary disease. Hum Genet 2001;108:216-21.
150. Schroeder SA, Gaughan DM, Swift M. Protection against bronchial asthma by CFTR delta F508 mutation: a heterozygote advantage in cystic fibrosis. Nat Med 1995;1:703-5.
151. Mennie M, Gilfillan A, Brock DJ, et al. Heterozygotes for the delta F508 cystic fibrosis allele are not protected against bronchial asthma. Nat Med 1995;1:978-9.
152. Dahl M, Tybjaerg-Hansen A, Lange P, et al. DeltaF508 heterozygosity in cystic fibrosis and susceptibility to asthma. Lancet 1998;351:1911-13.
153. Lázaro C, de Cid R, Sunyer J, et al. Missense mutations in the cystic fibrosis gene in adult patients with asthma. Hum Mutat 1999;14:510-19.
154. Casals T, Ramos MD, Gimenez J, et al. High heterogeneity for cystic fibrosis in Spanish families: 75 mutations account for 90% of chromosomes. Hum Genet 1997;101:365-70.
155. Marchand E, Verellen-Dumoulin C, Mairesse M, et al. Frequency of cystic fibrosis transmembrane conductance regulator gene mutations and 5T allele in patients with allergic bronchopulmonary aspergillosis. Chest 2001;119:762-7.
156. Castellani C, Quinzii C, Altieri S, et al. A pilot survey of cystic fibrosis clinical manifestations in CFTR mutation heterozygotes. Genet Test 2001;5:249-54.
157. Hinson KFW, Moon AJ, Plummet NS. Bronchopulmonary aspergillosis: a review and a report of eight new cases. Thorax 1952;7:317-33.
158. Geller DE, Kaplowitz H, Light MJ, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis: reported prevalence, regional distribution, and patient characteristics. Scientific Advisory Group, Investigators, and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Chest 1999;116:639-46.
159. Mastella G, Rainisio M, Harms HK, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis. A European epidemiological study. Epidemiologic Registry of Cystic Fibrosis. Eur Respir J 2000;16:464-71.
160. Starke ID. Asthma and allergic aspergillosis in monozygotic twins. Br J Dis Chest 1985;79:295-300.
161. Shah A, Khan ZU, Chaturvedi S, et al. Concomitant allergic Aspergillus sinusitis and allergic bronchopulmonary aspergillosis associated with familial occurrence of allergic bronchopulmonary aspergillosis. Ann Allergy 1990;64:507-12.
162. Miller PW, Hamosh A, Macek M Jr, et al. Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in allergic bronchopulmonary aspergillosis. Am J Hum Genet 1996;59:45-51.
163. Wang X, Moylan B, Leopold DA, et al. Mutation in the gene responsible for cystic fibrosis and predisposition to chronic rhinosinusitis in the general population. JAMA 2000;284:1814-19.
164. Raman V, Clary R, Siegrist KL, et al. Increased prevalence of mutations in the cystic fibrosis transmembrane conductance regulator in children with chronic rhinosinusitis. Pediatrics 2002;109:E13.
165. Hytönen M, Patjas M, Vento SI, et al. Cystic fibrosis gene mutations AF508 and 394delTT in patients with chronic sinusitis in Finland. Acta Otolaryngol 2001;121:945-7.
166. Bombieri C, Luisetti M, Belpinati F, et al. Increased frequency of CFTR gene mutations in sarcoidosis: a case/control association study. Eur J Hum Genet 2000;8:717-20.